OneMedNet Corporation (NASDAQ: ONMD) reported $16.2 million in year-to-date bookings for FY26, marking a 16X increase compared to the same period in 2025.

The US-based provider of regulatory-grade Real-World Data (RWD) attributed the surge to expanding demand from life sciences, medical device, and AI organizations using its iRWD™ Platform.

Customer Mix and Fulfillment

Approximately 50% of the contracts booked during 2026 were secured from new customers. The remaining volume came from existing clients who expanded their engagement through high reorder rates and follow-on activity.

Operational improvements have accelerated order fulfillment by approximately 50X. This increase in speed enables the company to assemble, qualify, and deliver fit-for-purpose multi-modal datasets more quickly, allowing it to accept larger orders while meeting customer project schedules.

What the Numbers Show

The simultaneous 16X growth in bookings and 50X improvement in fulfillment speed suggests OneMedNet is resolving previous operational bottlenecks. The equal split between new and existing customers indicates the company is acquiring fresh demand while successfully deepening wallet share with its current base, rather than relying solely on one segment for this volume spike.

Network Scale

The bookings reflect continued utilization of OneMedNet’s network, which spans more than 2,300 healthcare partner sites. The platform leverages data from over 90 million patient journeys and 270 million studies to support regulatory submissions, foundation-model development, cohort discovery, feasibility studies, and high-value research.

Aaron Green, CEO and President, stated that the commercial engine is delivering as the market shifts toward direct-from-source, regulatory-grade data.

OneMedNet Corporation (NASDAQ: ONMD) announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. The deal underscores growing demand for private healthcare data sourced directly from providers.

The customer selected OneMedNet for its ability to provide regulatory decision-grade data required for genuine innovation in drug development. The company’s iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and a signed contract within three weeks of initial contact.

Agreement Highlights

The agreement leverages OneMedNet’s network of more than 2,300 healthcare partner sites. The platform delivers multimodal data spanning Radiology, Cardiology, EEG, ECG, and de-identified electronic health records.

• Project feasibility completed within minutes.
• First-party data delivered from live Healthcare Provider partner sites.
• Regulatory decision-grade quality suitable for AI model development.
• Continued commercial momentum reflecting surging demand.

Network Scale

OneMedNet’s iRWD™ network now exceeds 90 million patient journeys and 270 million studies. This scale supports the customer’s development and validation of AI models designed to accelerate therapy discovery.

"Healthcare innovators are coming to OneMedNet because they see what it takes to build AI that performs in the real world: private clinical data sourced directly from healthcare providers," said Aaron Green, President & CEO of OneMedNet. "Our iRWD platform enables this pace — feasibility, validation, contracting, and delivery in a matter of weeks — and the ease of doing business customers can expect."

What the Numbers Show

The speed of execution highlights the operational efficiency of the platform. Moving from initial contact to signed contract in just three weeks suggests a streamlined commercial process compared to traditional data licensing timelines. The volume of 270 million studies across 2,300 sites indicates significant data density, which is critical for training robust AI models requiring diverse clinical inputs.